SP

Slate Path Capital

North America, New York, United States, New York

Description

Slate Path Capital provides portfolio management, securities, investment advice, and other financial services.

Investor Profile

Slate Path Capital has made 5 investments, with 1 in the past 12 months and 40% as lead.

Stage Focus

  • Post Ipo Equity (60%)
  • Series B (20%)
  • Series A (20%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Service Industry
  • Industrial
  • Mining
  • Sustainability
  • Biopharma
  • Life Science
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Slate Path Capital frequently co-invest with?

EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 1
Co-Investments: 1
6C
North America, New York, United States, New York
Co-Investments: 1
PC
North America, New York, United States, New York
Co-Investments: 1
ArrowMark Partners
North America, Colorado, United States, Denver
Co-Investments: 1
Sporos Bioventures
North America, Texas, United States, Houston
Co-Investments: 1
THE CATALYTIC IMPACT FOUNDATION (CIF)
North America, New York, United States, New York
Co-Investments: 1
Omega Advisors
North America, New York, United States, New York
Co-Investments: 1
Invus
North America, New York, United States, New York
Co-Investments: 2
Lincoln Park Capital Fund
North America, Illinois, United States, Chicago
Co-Investments: 1

Which angels does Slate Path Capital often collaborate with?

PM
North America, Massachusetts, United States, Cambridge
Shared Deals: 1
CP
North America, California, United States
Shared Deals: 1

What are some of recent deals done by Slate Path Capital?

City Therapeutics

Cambridge, Massachusetts, United States

City Therapeutics is a biopharmaceutical company focused on developing next-generation small interfering RNAs.

BiopharmaLife ScienceTherapeutics
Series AOct 8, 2024
Amount Raised: $135,000,000
Tvardi Therapeutics

Houston, Texas, United States

Tvardi Therapeutics is a Private, Clinical Stage Biotechnology Company.

BiotechnologyHealth CarePharmaceuticalService Industry
Series BJun 15, 2021
Amount Raised: $72,418,254
Cyclerion Therapeutics

Cambridge, Massachusetts, United States

Cyclerion Therapeutics harnesses the potential of soluble guanylate cyclase (sGC) pharmacology.

BiotechnologyPharmaceutical
Post Ipo EquityJun 4, 2021
Amount Raised: $18,000,000
MP Materials

Las Vegas, Nevada, United States

MP Materials provides a sustainable, low-cost supply chain of coveted materials that help power the modern economy.

IndustrialMiningSustainability
Post Ipo EquityNov 17, 2020
Amount Raised: $200,000,000
Cyclerion Therapeutics

Cambridge, Massachusetts, United States

Cyclerion Therapeutics harnesses the potential of soluble guanylate cyclase (sGC) pharmacology.

BiotechnologyPharmaceutical
Post Ipo EquityJul 31, 2020
Amount Raised: $24,000,000